CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
500 produits trouvés pour "CDK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK7-IN-2 hydrochloride hydrate
CAS :<p>CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.</p>Formule :C26H42ClN7O4Couleur et forme :SolidMasse moléculaire :552.123-Methylthienyl-carbonyl-JNJ-7706621
CAS :<p>Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.</p>Formule :C14H14N6O3S2Couleur et forme :SolidMasse moléculaire :378.43LSN3106729 hydrochloride
CAS :<p>LSN3106729 hydrochloride, an Abemaciclib metabolite, is a CDK-inhibiting antitumor PROTAC CDK4/6 degrader.</p>Formule :C25H29ClF2N8OCouleur et forme :SoildMasse moléculaire :531.00Olomoucine
CAS :<p>Olomoucine hinders Cdk2, Cdc2, CDK5, ERK1, regulates the cell cycle, and fights melanoma; IC50s: 3-25 µM.</p>Formule :C15H18N6ODegré de pureté :99.77%Couleur et forme :White Crystalline PowderMasse moléculaire :298.34PP-C8
<p>PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.</p>Formule :C43H51FN12O7Couleur et forme :SolidMasse moléculaire :866.94PROTAC CDK9 degrader-7
CAS :<p>PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (</p>Formule :C43H50Cl2N8O9Couleur et forme :SoildMasse moléculaire :893.81BSJ-03-204
CAS :<p>BSJ-03-204 is a selective Cdk4/6 degrader.</p>Formule :C43H48N10O8Couleur et forme :SolidMasse moléculaire :832.9CGP-74514
CAS :<p>CGP-74514,CDK1 inhibitor (IC50=25 nM). Induces G2/M arrest, apoptosis. Used in bladder cancer research.</p>Formule :C19H24ClN7Degré de pureté :98.54%Couleur et forme :SoildMasse moléculaire :385.89PROTAC CDK9 degrader 4
CAS :<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Formule :C43H56N10O5Couleur et forme :SolidMasse moléculaire :792.97JH-XVI-178
CAS :<p>JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.</p>Formule :C22H22ClN7OCouleur et forme :SolidMasse moléculaire :435.92FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Couleur et forme :LiquidKinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Couleur et forme :Odour SolidCDK7-IN-6
CAS :<p>CDK7-IN-6, a potent CDK7 inhibitor (IC50 ≤100 nM), from WO2019197549 A1, is >200x selective over CDK1/2/5, promising for cancer research.</p>Formule :C26H34ClN9OCouleur et forme :SolidMasse moléculaire :524.07PROTAC CDK9 degrader-5
CAS :<p>PROTAC CDK9 degrader-5 selectively degrades CDK9 isoforms 42, 55 with DC50 of 0.10μM, 0.14μM via proteasome.</p>Formule :C42H48Cl2N8O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :879.78AM5992
CAS :<p>AM5992 (example 195) is a potent CDK4 and CDK6 inhibitor (CDK4, IC50= 0.013 μM). AM5992 can be used for the research of CDK4-mediated disorders.</p>Formule :C27H33FN8ODegré de pureté :98%Couleur et forme :SoildMasse moléculaire :504.6HTH-01-091 TFA
<p>HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.</p>Formule :C28H29Cl2F3N4O4Couleur et forme :SolidMasse moléculaire :613.46CDK-IN-12
CAS :<p>CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].</p>Formule :C26H29FN6OSCouleur et forme :SolidMasse moléculaire :492.61CDK12-IN-4
CAS :<p>CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).</p>Formule :C20H20F2N8OCouleur et forme :SolidMasse moléculaire :426.432SNX7
CAS :<p>SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.</p>Formule :C15H14N2ODegré de pureté :99.05%Couleur et forme :SolidMasse moléculaire :238.28CDK6/9-IN-1
CAS :<p>CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).</p>Formule :C22H25ClN8OCouleur et forme :SolidMasse moléculaire :452.95LL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Formule :C37H43N5OCouleur et forme :SolidMasse moléculaire :573.77CDK4/6-IN-11
CAS :<p>CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.</p>Formule :C43H49N11O7Couleur et forme :SolidMasse moléculaire :831.92PROTAC FLT3/CDKs degrader-1
<p>PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.</p>Formule :C40H42N12O5Masse moléculaire :770.34011Men 10376
CAS :<p>Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.</p>Formule :C57H68N12O10Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1081.22CDK7-IN-5
CAS :<p>CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).</p>Formule :C34H45N9O2Couleur et forme :SolidMasse moléculaire :611.795PROTAC CDK9 degrader-2
CAS :<p>PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.</p>Formule :C39H36N6O10Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :748.74XY028-133
CAS :<p>XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.</p>Formule :C53H67N11O7SDegré de pureté :97.11%Couleur et forme :SolidMasse moléculaire :1002.23Cdk2/Cyclin Inhibitory Peptide II
CAS :<p>Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].</p>Formule :C110H200N48O25Couleur et forme :SolidMasse moléculaire :2595.07EGFR/CDK2-IN-4
<p>EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.</p>Formule :C24H16N6OS2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :468.55BSJ-04-132
<p>Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.</p>Couleur et forme :LiquidCDK4/6-IN-5
CAS :<p>CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)</p>Formule :C22H28ClFN6O4SCouleur et forme :SolidMasse moléculaire :527.01Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Degré de pureté :98%Couleur et forme :Odour SolidCDK12-IN-6
CAS :<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Formule :C20H21F2N9Couleur et forme :SolidMasse moléculaire :425.448TMX-2138
CAS :<p>TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.</p>Formule :C40H43BrFN9O11SCouleur et forme :SolidMasse moléculaire :956.791CDK9 inhibitor HH1
CAS :<p>CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.</p>Formule :C13H15N3OSDegré de pureté :99.92%Couleur et forme :SolidMasse moléculaire :261.34Abemaciclib metabolite M18
CAS :<p>Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.</p>Formule :C25H28F2N8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :494.54PROTAC CDK9 degrader-8
<p>PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].</p>Formule :C44H52Cl2N10O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :903.85CDK9-IN-25
<p>CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.</p>Formule :C15H16FN5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :285.32EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Formule :C49H32N12O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :884.99Cdk2/Cyclin Inhibitory Peptide I
<p>CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.</p>Formule :C111H196N48O23Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2571.05CDK7-IN-7
CAS :<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Formule :C20H20BrF3N6O2Couleur et forme :SolidMasse moléculaire :513.319[pThr3]-CDK5 Substrate
CAS :<p>[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM[1].</p>Formule :C53H100N15O15PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1218.43PROTAC CDK9 degrader-11
CAS :<p>PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)</p>Formule :C39H48Cl2N10O5Couleur et forme :SolidMasse moléculaire :807.768IV-361
CAS :<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Formule :C23H32FN5O2SiCouleur et forme :SolidMasse moléculaire :457.625EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Formule :C30H20N6OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :512.58CDK5-IN-1
CAS :<p>CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.</p>Formule :C24H25FN6O3SCouleur et forme :SolidMasse moléculaire :496.56YKL-5-124 TFA
CAS :<p>YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.</p>Formule :C30H34F3N7O5Couleur et forme :SolidMasse moléculaire :629.63Cell Cycle Compound Library
<p>A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);</p>Couleur et forme :Odour SolidCDK2-IN-43
<p>CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.</p>Formule :C19H27N7OCouleur et forme :SolidMasse moléculaire :369.464CDK1-IN-2
CAS :<p>CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.</p>Formule :C17H11ClN2ODegré de pureté :98.53%Couleur et forme :SoildMasse moléculaire :294.73
![[pThr3]-CDK5 Substrate](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1602.webp&w=3840&q=75)
